Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600513 Jiangsu Lianhuan Pharmaceutical Co Ltd SHSE:600513
65 GF Score
Price ¥15.42
GF Value ¥13.72
Valuation Modestly Overvalued
! 10 Warning Signs
View Full Analysis

What is Jiangsu Lianhuan Pharmaceutical Co FFO?

FFO (Funds from operations) only applies to REITs.

SHSE:600513
65GF Score
Jiangsu Lianhuan Pharmaceutical Co Ltd SHSE:600513
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) Overvalued in 2026?

Based on GuruFocus' analysis, Jiangsu Lianhuan Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥15.42 is trading 12.4% above its estimated GF Value™ of ¥13.72. GuruFocus considers Jiangsu Lianhuan Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SHSE:600513:

  • FFO:
  • GF Value™: ¥13.72 vs. price of ¥15.42 (12.4% above fair value)
  • GF Score™: 65/100 with 10 warning signs

No single metric tells the full story. See the SHSE:600513 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jiangsu Lianhuan Pharmaceutical Co Business Description

Address No. 9, Jiankang 1st Road, Yangzhou Bio-Health Industry Park, Jiangsu Province, Yangzhou, Jiangsu, CHN, 225127
Jiangsu Lianhuan Pharmaceutical Co Ltd is engaged in producing benign prostatic hyperplasia, allergy and cardiovascular drugs. In the field of pharmaceutical manufacturing, the company's main products include several series such as urinary system drugs, antihistamines, cardiovascular drugs, steroid hormones, antibiotics, etc., covering chemical raw materials and injections, solid preparations and various drug dosage forms, including the national first-class new drug Apelite Tablets (Chuanliu).
65GF Score

Get the complete analysis for SHSE:600513

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥15.42
Price
¥13.72
GF Value